While the clinical benefit rate of a trial of 25 patients with MPNST using the combination of everolimus (mTOR inhibitor) and bevacizumab (VEGF inhibitor) was only 12%46, deeper understanding of the role of RGS5 + cells in metastasis and immunomodulation of the MPNST TME may provide novel therapeutic avenues. This evidence concerns the gene MTOR and malignant peripheral nerve sheath tumor.